Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~COHORT 1: HIV seronegative~1. Older than 18 years;~2. HSV-2 seropositive by Western Blot;~3. not receiving any drugs with known anti-HSV-2 activity for study duration;~4. women of child bearing potential who are sexually active with men must be using a medically accepted method of contraception as judged by the investigator;~5. women of child-bearing potential must have a negative pregnancy test (urine) at screening visit;~6. in general good health, without other serious medical conditions and specifically with normal renal and hepatic function, as determined by the patient's medical history;~7. planning to remain resident in the area of the study center for the duration of the study participation;~8. HIV seronegative~COHORT 2: HIV seropositive~1. Older than18 years;~2. HSV-2 seropositive by Western Blot;~3. not receiving any drugs with known anti-HSV-2 activity for study duration;~4. women of child bearing potential who are sexually active with men must be using a medically accepted method of contraception as judged by the investigator;~5. women of child-bearing potential must have a negative pregnancy test (urine) at screening visit;~6. in general good health, without other serious medical conditions and specifically with normal renal and hepatic function, as determined by the patient's medical history;~7. planning to remain resident in the area of the study center for the duration of the study participation;~8. HIV seropositive~9. CD4 count over 250 cell/mm3~10. Not taking antiretroviral therapy~Exclusion Criteria:~For both cohorts:~1. hypersensitivity to acyclovir or valacyclovir;~2. pregnant women;~3. Taking immunosuppressive therapies, such as chronic oral steroids or immune modulatory drugs.~For cohort 2:~1. CD4 count\<250 cell/mm3~2. Taking antiretroviral therapy at the time of study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).